Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Ltd. Fundamental Analysis
Senores Pharmaceuticals Ltd. (SENORES.NS) shows weak financial fundamentals with a PE ratio of 34.43, profit margin of 18.56%, and ROE of 12.70%. The company generates $5.8B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -31.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SENORES.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakSENORES.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakSENORES.NS trades at a premium to fair value.
Growth Score
ModerateSENORES.NS shows steady but slowing expansion.
Financial Health Score
ExcellentSENORES.NS maintains a strong and stable balance sheet.
Profitability Score
WeakSENORES.NS struggles to sustain strong margins.
Key Financial Metrics
Is SENORES.NS Expensive or Cheap?
P/E Ratio
SENORES.NS trades at 34.43 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SENORES.NS's PEG of 2.48 indicates potential overvaluation.
Price to Book
The market values Senores Pharmaceuticals Ltd. at 4.30 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 19.72 times EBITDA. This signals the market has high growth expectations.
How Well Does SENORES.NS Make Money?
Net Profit Margin
For every $100 in sales, Senores Pharmaceuticals Ltd. keeps $18.56 as profit after all expenses.
Operating Margin
Core operations generate 23.73 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.70 in profit for every $100 of shareholder equity.
ROA
Senores Pharmaceuticals Ltd. generates $7.89 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Senores Pharmaceuticals Ltd. generates limited operating cash flow of $-297.83M, signaling weaker underlying cash strength.
Free Cash Flow
Senores Pharmaceuticals Ltd. generates weak or negative free cash flow of $-2.41B, restricting financial flexibility.
FCF Per Share
Each share generates $-52.37 in free cash annually.
FCF Yield
SENORES.NS converts -6.13% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
34.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.48
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.30
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.78
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.30
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How SENORES.NS Stacks Against Its Sector Peers
| Metric | SENORES.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 34.43 | 28.23 | Worse (Expensive) |
| ROE | 12.70% | 737.00% | Weak |
| Net Margin | 18.56% | -46175.00% (disorted) | Strong |
| Debt/Equity | 0.30 | 0.35 | Neutral |
| Current Ratio | 2.39 | 4.10 | Strong Liquidity |
| ROA | 7.89% | -17785.00% (disorted) | Weak |
SENORES.NS outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Senores Pharmaceuticals Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation